14:55 ET -- Moderna is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Shares were up 8% to $84.96 after Moderna and partner Merck disclosed positive trial results for an experimental mRNA-based treatment for skin cancer. On Wednesday, shares of Moderna and other makers of Covid-19 vaccines declined after Pfizer warned about slower demand for its Covid-19 products. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)

(END) Dow Jones Newswires

December 14, 2023 15:11 ET (20:11 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Moderna 차트를 더 보려면 여기를 클릭.
Moderna (NASDAQ:MRNA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Moderna 차트를 더 보려면 여기를 클릭.